Johnson & Johnson is starting 2022 in a strong financial position with flexibility to act boldly on business development to build out the pharmaceutical portfolio, CEO Joaquin Duato said during the company's fourth quarter sales and earnings call on 25 January. The quarterly call was the first for Duato as chief executive after taking over the role from Alex Gorsky at the start of the year.
"We are about to turn from a net debt to a net cash position for the first time in over...








